KML001 Enhances Anticancer Activity of Gemcitabine Against Pancreatic Cancer Cells

Abstract

Background/Aim: Gemcitabine is a drug commonly used to treat pancreatic cancer but chemoresistance to it is a common clinical issue. KML001 (sodium meta-arsenite) has demonstrated certain antitumor activity. The objective of the study was to evaluate the influence of KML001 on the anticancer activity of gemcitabine against pancreatic cancer cells. Materials and Methods: Cell proliferation, migration, and invasion were assessed, as well as the expression of nuclear factor-kappa B (NF-kappa B) p65, epidermal growth factor receptor (EGFR), matrix metalloproteinase-2 (MMP2), and vascular endothelial growth factor-C (VEGFC) in pancreatic cancer cells. Results: Treatment with a combination of KML001 and gemcitabine resulted in significant inhibition of cell proliferation, migration, and invasion, and significantly reduced EGFR and MMP2 expression compared to gemcitabine treatment-alone. Conclusion: Combination treatment of gemcitabine and KML001 could be an effective chemotherapeutic treatment for pancreatic cancer.